Trial · NCT00157573
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Median Time to Treatment Termination (TTT) | GM-CSF, Sargramostim | 78 | Full Range 14 to 460 | days | |
| Tumor Response Rate (RR) | GM-CSF, Sargramostim | Complete Response | 1 | Participants | |
| Tumor Response Rate (RR) | GM-CSF, Sargramostim | Partial Response | 0 | Participants | |
| Tumor Response Rate (RR) | GM-CSF, Sargramostim | Stable Disease | 20 | Participants | |
| Tumor Response Rate (RR) | GM-CSF, Sargramostim | Progressive Disease | 50 | Participants | |
| Number of Participants With Adverse Events (Toxicity) Grade 3 or 4 | GM-CSF, Sargramostim | Thrombocytopenia | 2 | Participants | |
| Number of Participants With Adverse Events (Toxicity) Grade 3 or 4 | GM-CSF, Sargramostim | Musculoskeletal pain | 9 | Participants | |
| Number of Participants With Adverse Events (Toxicity) Grade 3 or 4 | GM-CSF, Sargramostim | Fatigue | 3 | Participants | |
| Number of Participants With Adverse Events (Toxicity) Grade 3 or 4 | GM-CSF, Sargramostim | Abnormal liver function test | 2 | Participants | |
| Number of Participants With Adverse Events (Toxicity) Grade 3 or 4 | GM-CSF, Sargramostim | Vomiting | 2 | Participants | |
| Number of Participants With Adverse Events (Toxicity) Grade 3 or 4 | GM-CSF, Sargramostim | Metabolic | 2 | Participants | |
| Number of Participants With Adverse Events (Toxicity) Grade 3 or 4 | GM-CSF, Sargramostim | Small bowel obstruction | 2 | Participants | |
| Number of Participants With Adverse Events (Toxicity) Grade 3 or 4 | GM-CSF, Sargramostim | Myelodysplasia | 1 | Participants | |
| Number of Participants With Adverse Events (Toxicity) Grade 3 or 4 | GM-CSF, Sargramostim | Urticaria | 1 | Participants | |
| Number of Participants With Adverse Events (Toxicity) Grade 3 or 4 | GM-CSF, Sargramostim | Abdominal pain | 1 | Participants | |
| Number of Participants With Adverse Events (Toxicity) Grade 3 or 4 | GM-CSF, Sargramostim | Palpitations | 1 | Participants | |
| Number of Participants With Adverse Events (Toxicity) Grade 3 or 4 | GM-CSF, Sargramostim | Hypertension | 1 | Participants | |
| Number of Participants With Adverse Events (Toxicity) Grade 3 or 4 | GM-CSF, Sargramostim | Changes in bowel habit | 1 | Participants | |
| Number of Participants With Adverse Events (Toxicity) Grade 3 or 4 | GM-CSF, Sargramostim | Diverticulitis | 1 | Participants | |
| Number of Participants With Adverse Events (Toxicity) Grade 3 or 4 | GM-CSF, Sargramostim | Gout | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00157573/results